Switzerland-based Addex Therapeutics Ltd is to reduce its operating costs by spinning out a group of preclinical assets into a new venture capital-based company thereby enabling it to accelerate development of its lead product for epilepsy. The reorganisation, announced on 3 April, will stratify Addex’s pipeline giving the company more financial support and time to develop its pipeline of small molecule drugs for neurological diseases.
